In the last trading session, 0.26 million Silverback Therapeutics Inc. (NASDAQ:SBTX) shares changed hands as the company’s beta touched 0. With the company’s per share price at $4.12 changed hands at -$0.12 or -2.83% during last session, the market valuation stood at $149.02M. SBTX’s last price was a discount, traded about -764.81% off its 52-week high of $35.63. The share price had its 52-week low at $2.80, which suggests the last value was 32.04% up since then. When we look at Silverback Therapeutics Inc.’s average trading volume, we note the 3-month average coming to 503.10K.
Analysts gave the Silverback Therapeutics Inc. (SBTX) stock a consensus recommendation rating of a Hold, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 5 recommended SBTX as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight. Silverback Therapeutics Inc.’s EPS for the current quarter is expected to be -$0.54.
Silverback Therapeutics Inc. (NASDAQ:SBTX) trade information
Instantly SBTX was in red as seen at the end of in last trading. With action -5.29%, the performance over the past five days has been red. The drop to weekly highs of 4.53 on Friday, 07/01/22 subtracted -2.83% to the stock’s daily price. The company’s shares are showing year-to-date downside of -38.14%, with the 5-day performance at -5.29% in the red. However, in the 30-day time frame, Silverback Therapeutics Inc. (NASDAQ:SBTX) is 19.08% up.
The consensus price target for the stock as assigned by Wall Street analysts is $3.27, meaning bulls need a downside of -25.99% from its current market value. According to analyst projections, SBTX’s forecast low is $1.80 with $5.00 as the target high. To hit the forecast high, the stock’s price needs a -21.36% plunge from its current level, while the stock would need to tank 56.31% for it to hit the projected low.
Silverback Therapeutics Inc. (SBTX) estimates and forecasts
Data shows that the Silverback Therapeutics Inc. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -37.58% over the past 6 months, a 19.14% in annual growth rate that is considerably higher than the industry average of 0.90%.
The 2022 estimates are for Silverback Therapeutics Inc. earnings to decrease by -169.80%.
Silverback Therapeutics Inc. is expected to release its next quarterly earnings report between March 28 and April 01.
Silverback Therapeutics Inc. (NASDAQ:SBTX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 3.63% of Silverback Therapeutics Inc. shares while 91.09% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 94.53%. There are 91.09% institutions holding the Silverback Therapeutics Inc. stock share, with Orbimed Advisors LLC. the top institutional holder. As of Dec 30, 2021, the company held 24.87% of the shares, roughly 8.74 million SBTX shares worth $58.21 million.
FMR, LLC holds the second largest percentage of outstanding shares, with 10.68% or 3.75 million shares worth $25.0 million as of Dec 30, 2021.
Among Mutual Funds, the top two as of Feb 27, 2022 were Fidelity Growth Company Fund and Wasatch Ultra Growth Fund. With 1.47 million shares estimated at $6.33 million under it, the former controlled 4.19% of total outstanding shares. On the other hand, Wasatch Ultra Growth Fund held about 3.35% of the shares, roughly 1.18 million shares worth around $4.13 million.